The endoscopic stenting of patients with unresectable malignant biliary obstruction with 10 and 12 French gauge (FG) polyethylene endoprostheses is now commonplace.1-3 The development of stent occlusion, however, in 20-30% of patients within three months of stent insertion is an important problem with this approach to treatment. 4 Self expanding metal stents (Wallstents) may be inserted percutaneously or endoscopically and have been used in the treatment of patients with malignant biliary obstruction since 1989.>7 Self expanding metal stents have a longer patency than polyethylene stents in short term follow up, however, the longterm patency of metal stents is unknown.8"1 Furthermore, as most patients stented for malignant biliary obstruction will die with their first stent in situ one of the important issues regarding the use of metal stents in this population of patients is the question of cost effectiveness. 9 11 12 The aim of this study was to assess the longterm efficacy and complications of metal stents in the treatment of patients with unresectable malignant biliary strictures.
Methods

PATIENTS
Between may 1989 and May 1992, metal stents were inserted in 28 patients (median age 66 years, range 40-80) with unresectable malignant biliary obstruction (Table I) . Bile duct obstruction was secondary to pancreatic carcinoma in 10 patients, ampullary carcinoma in 10 patients, cholangiocarcinoma in seven patients, and extrinsic compression of the biliary tree from secondary carcinoma in one patient. The cholangiocarcinoma was located high in the bile duct in six patients and low in the bile duct in one patient. The median time from diagnosis of malignant bile duct stricture to insertion of a metal stent was six months (range 1-72) and the median number of polyethylene stents inserted during this time period was two (range 0-12) (Table I) .
METAL STENT INSERTION
A metal stent (Wallstent, Schneider, UK) is made of surgical grade stainless steel alloy 
Results
METAL STENT PATENCY
The median period of stent patency for the 28 patients was 8-2 months (range 1 0-32 5). The median follow up was 14.6 months (range 10-38 5) and at this stage 22 of 28 (78.6%) patients with malignant disease remained free of jaundice or cholangitis (Table II) . There was no clinical evidence of stent occlusion in 15 of 28 patients throughout the total follow up period of up to 38.5 months.
Thirteen patients (46.4%) with malignant disease developed symptomatic metal stent occlusion as evidenced clinically by jaundice or cholangitis, or both at a median of 6-4 months (4-304). The median follow up time of the group of patients who developed metal stent occlusion was not significantly different from that of the group who did not develop metal stent occlusion, 14 1 months (range 5 1-38-5) and 12-0 months (range 1 0-32.7) respectively (Table II) . The number of patients with cholangiocarcinoma treated with external beam radiation or iridium implants, or both was comparable in both groups.
Ten of 13 patients with symptomatic metal stent occlusion were examined with a mother and baby scope and had further endoscopic intervention. Of the remaining three patients, one patient was terminally ill, one patient had an early elective Whipple's procedure performed, and the third patient declined endoscopic intervention. Jaundice and fever subsequently settled in this patient with antibiotics and rehydration.
Balloon trawling of the metal stent was performed in four patients at a median of 9.2 months to remove sludge and debris above soft frond like tumour invasion of the stent. Three of the four patients did not have any further episodes of stent occlusion after a further median follow up of 8.5 months. Stent reocclusion occurred in one patient after two months and a polyethylene stent was inserted. In the other six patients the major cause of metal stent occlusion was the presence of more solid tumour occupying the stent lumen. In these six patients a polyethylene stent was inserted through the metal stent after a median of seven months. Stent reocclusion occurred in three of six patients after a median of three months requiring a change of the polyethylene stent.
SURVIVAL AND COMPLICATIONS
The median survival of the 28 patients (86%) had died and all but one death was related to the primary malignancy. This patient died from cardiac failure and at postmortem examination the metal stent was noted to be patent. Throughout the follow up period few complications specifically related to the presence of a metal stent were seen. Minimal right upper quadrant discomfort was a common complaint during the first four weeks after stent insertion and was almost certainly caused by the continued spontaneous expansion of the metal stent during this period of time. None of the patients developed post-stenting cholangitis. One patient with a type III hilar cholangiocarcinoma developed cholangitis and septicaemia secondary to an undrained left lobe of liver. A percutaneous transhepatic prosthesis was inserted into the left lobe through the mesh of the stent with excellent drainage. One further patient with pre-existing cholecystolithiasis developed an empyema of the gall bladder necessitating percutaneous gall bladder drainage and subsequent laparoscopic cholecystectomy. Gastric outlet obstruction occurred in 12 patients, nine of whom had a gastroenterostomy performed.
Discussion
The occlusion of stents with biliary sludge is the major problem with the use of polyethylene endoprostheses in the treatment of patients with unresectable malignant biliary obstruction. 4 The internal diameter of a stent has been shown to be a critical factor in the development of stent occlusion.'3 14 The maximum possible diameter of the prosthesis, however, which may be inserted is determined by the diameter of the endoscope instrumentation channel. Therefore the development of self expanding metal stents has permitted the endoscopic insertion of prostheses, which ultimately have a considerably larger internal diameter. The Wallstent is loaded on a 9 FG delivery system, with the result that it is comparatively easy to insert and position and when released in situ it expands to a maximum internal diameter of 1 cm. Although difficulty with stent insertion has been reported by some authors,15 the success rate for the insertion of metal stents in the present series was 100%. In addition, technical problems with stent deformity or migration were not found and post-stenting cholangitis was not seen.16 17 The use of metal stents in patients with malignant biliary obstruction in this series has been associated with very favourable results with 78.6% of patients remaining jaundice free after a median follow up of 14.6 months. The median period of metal stent patency was 8.2 months, which is superior to that expected in patients stented with polyethylene endoprostheses (4-5 months) and is comparable with metal stent patency reported in recent randomised controlled trials.' [0] [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] The 30 day mortality of 3.5% in this series was very low compared with 10-14% mortality in other series.11 18 The overall survival of patients treated with metal stents in this study was longer than that reported in other series1 17 and is attributable both to the lower proportion of patients with pancreatic carcinoma in this series together with our policy of careful patient selection for this form of treatment.
Episodes of symptomatic metal stent occlusion were easily treated endoscopically with either balloon trawling of the metal stent to remove biliary sludge and debris or by the insertion of a polyethylene stent through a tumour occluded metal stent lumen. The patency rates for polyethylene stents used in this situation were similar to those seen in other studies. In a recent study from our unit, 67% of patients died with their initial polyethylene stent in situ and only 33°/o needed readmission for a stent change at a mean of 4.5 months.'2 It is therefore not economical to put metal stents into all patients presenting with malignant obstructive jaundice as most would be successfully palliated with a single polyethylene stent. Ideally the longer term survivors should be selected out for metal stent insertion. In practice this is difficult and our policy is to place metal stents in patients we judge to have a better prognosis -that is, patients with an unresectable ampullary tumour or a cholangiocarcinoma. Those patients with pancreatic adenocarcinoma who show little evidence of disease progression, when they represent for their first conventional stent change, we would also consider for insertion of a metal stent.
In conclusion, metal stents give prolonged palliation and superior results compared with polyethylene stents in patients with unresectable malignant biliary obstruction. To optimise cost effectiveness it is essential that patients are carefully selected for this form of treatment.
